Publicaciones en colaboración con investigadores/as de Medical Research Council (16)

2023

  1. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

2022

  1. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

    BMC Medical Research Methodology, Vol. 22, Núm. 1

  2. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352

  3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

2021

  1. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

2018

  1. Microbial translocation does not drive immune activation in ugandan children infected with HIV

    Journal of Infectious Diseases, Vol. 219, Núm. 1, pp. 89-100

  2. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

    HIV Medicine, Vol. 19, Núm. 1, pp. e1-e42

2016

  1. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project

    BMC Infectious Diseases, Vol. 16, Núm. 1

2015

  1. Early antiretroviral therapy in children perinatally infected with HIV: A unique opportunity to implement immunotherapeutic approaches to prolong viral remission

    The Lancet Infectious Diseases, Vol. 15, Núm. 9, pp. 1108-1114

2013

  1. Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children

    AIDS and Behavior, Vol. 17, Núm. 1, pp. 193-202

  2. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants

    AIDS, Vol. 27, Núm. 6, pp. 991-1000

2012

  1. Migrant mortality from diabetes mellitus across Europe: The importance of socio-economic change

    European Journal of Epidemiology, Vol. 27, Núm. 2, pp. 109-117

2011

  1. Risk of triple-class virological failure in children with HIV: A retrospective cohort study

    The Lancet, Vol. 377, Núm. 9777, pp. 1580-1587

2004

  1. Monitoring of trends in socioeconomic inequalities in mortality: Experiences from a European project

    Demographic Research, Vol. 10, Núm. SUPPL. 2, pp. 229-254

2002

  1. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial

    Journal of Infectious Diseases, Vol. 186, Núm. 3, pp. 312-320

  2. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection

    HIV Medicine, Vol. 3, Núm. 3, pp. 215-226